MORE►
AVR-48
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
Fort Worth’s AyuVis Gets FDA Fast‑Track Designation for Its Drug for Babies with a Chronic Lung Disease
by David Seeley | Aug 23, 2024
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
by Lance Murray |
May 17, 2023
The grant from the National Heart, Lung, and Blood Institute will fund a first-in-human Phase 1 clinical trial of a new generation of immunotherapies. This is the fourth NIH grant AyuVis has received since its founding in 2014, doubling total non-dilutive funding to $4.2 million. Co-Founder and CEO Dr. Suchismita Acharya calls the move to a human trial "a huge milestone for AyuVis."
MORE►
by Kevin Cummings |
May 12, 2022
AyuVis, an immunotherapy startup, is set to get a $1.8 million Small Business Innovation Research grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The funding will support the pre-clinical research of its drug candidate to treat the second-leading cause of death in premature babies.
Founder Suchismita Acharya calls the timing "perfect."
Founder Suchismita Acharya calls the timing "perfect."
MORE►
